文献速递临床试验与 GCP

代谢综合征患者减重后的预期寿命:一项随机临床试验的研究方案(LIFEXPE-RT)

The life expectancy of patients with metabolic syndrome after weight loss: study protocol for a randomized clinical trial (LIFEXPE-RT).
PubMed 文献 · Trials · 2019-04-08

本研究为三臂随机对照试验,旨在评估代谢综合征患者减重后端粒长度等指标的变化。第一组接受无钉吻合的胃旁路术(LOAGB-OSPAN),第二组接受标准胃旁路术(LMGB-OAGB),第三组接受非手术减重治疗(每日能量限制-500 kcal的低热量饮食)。研究将比较各组端粒长度、体重指数、合并症和生活质量的变化。

要点

  • 三臂随机对照试验比较两种手术减重与非手术减重对端粒长度的影响。
  • 非手术组采用每日能量限制-500 kcal的低热量饮食。
  • 主要比较指标包括端粒长度、体重指数、合并症和生活质量的变化。

核心结论

  • 据作者所知,这是首个同时比较手术与非手术减重对端粒长度变化影响的随机研究。
  • 该研究可能为日益严重的代谢综合征问题提供解决方案。
  • 体重指数正常化可改善代谢综合征患者的健康。

研究设计与样本

  • 本研究为三臂随机对照试验。
  • 第一组患者接受无钉吻合的胃旁路术(LOAGB-OSPAN)。
  • 第二组患者接受标准胃旁路术(LMGB-OAGB)。
  • 第三组患者接受非手术减重治疗,包括每日能量限制-500 kcal的低热量饮食。
  • 研究旨在比较代谢综合征患者减重后端粒长度、体重指数、合并症和生活质量的变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To date, surgeons and physicians have found positive results treating metabolic syndrome with surgical and non-surgical weight loss therapies. The purpose of this study was to evaluate changes in telomere length in patients with metabolic syndrome after weight loss. METHODS/DESIGN: This study is a three-arm randomized controlled trial. The first group is composed of patients who have undergone stapleless bypass surgery (one anastomosis gastric bypass with an obstructive stapleless pouch and anastomosis (LOAGB-OSPAN)). The second group of patients underwent standard gastric bypass surgery (laparoscopic mini-gastric bypass-one anastomosis gastric bypass (LMGB-OAGB). The patients in the third group received non-surgical weight loss therapy, including a hypocaloric diet with energy restriction (- 500 kcal/day). The aim is to compare changes-telomere length, body mass index, comorbidities, and quality of life-in patients with metabolic syndrome after weight loss. DISCUSSION: To the best of our knowledge, this is the first randomized study to simultaneously compare the effects of surgical and non-surgical weight loss on changes in telomere length. It could provide a solution to the growing problem of metabolic syndrome. Normalization of the body mass index results in improvements in the health of patients with metabolic syndrome. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03667469 . Registered on 11 September 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ospanov O, Yeleuov G, Kadyrova I, et al. The life expectancy of patients with metabolic syndrome after weight loss: study protocol for a randomized clinical trial (LIFEXPE-RT). Trials. 2019. PMID: 30961631. doi:10.1186/s13063-019-3304-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。